Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS known ✓ | P14324 | 2/20 | 0.36 |
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.32 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP14 | P50281 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL240572 | 0.98 | FDPS (0.37) | FDPSCYP19A1 | |
| Water SCHEMBL921702 | 0.82 | FDPS (0.38) | FDPSBTN3A1CA12GGPS1CA2 | |
| Water SCHEMBL2111846 | 0.78 | FDPS (0.42) | FDPSBTN3A1CA12GGPS1CA2 | |
| SCHEMBL240573 | 0.76 | FDPS (0.43) | FDPSBTN3A1CA12GGPS1CA2 | |
| SCHEMBL7245729 | 0.67 | FDPS (0.44) | FDPSBTN3A1CA12GGPS1CA2 | |
| SCHEMBL28888016 | 0.66 | FDPS (0.43) | FDPSBTN3A1CA12GGPS1CA2 | |
| SCHEMBL2949292 | 0.66 | FDPS (0.47) | FDPSBTN3A1CA12GGPS1CA2 | |
| SCHEMBL29263780 | 0.66 | KMT2A (0.41) | CYP19A1 | |
| Water SCHEMBL27959592 | 0.65 | FDPS (0.42) | FDPSBTN3A1CA12GGPS1CA2 | |
| Phosphoric Acid SCHEMBL28121884 | 0.63 | FDPS (0.43) | FDPSBTN3A1CA12GGPS1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005051229-A2 | DEVICES DELIVERING THERAPEUTIC AGENTS AND METHODS REGARDING THE SAME | AVANTEC VASCULAR CORPORATION (US) | 2005-06-09 | — | — | WO | claimed |
| US-20250295678-A1 | ULTRA LOW DOSAGE ZOLEDRONIC ACID FOR TREATMENT OF RETINAL DISEASE | THE WISCONSIN ALUMNI RESEARCH FOUNDATION | 2025-09-25 | — | — | US | disclosed |
| CN-119546310-A | Ultra-low dose zoledronic acid for treating retinal diseases | 加利福尼亚大学董事会 | 2025-02-28 | — | — | CN | disclosed |
| EP-4427812-A2 | SUBSTITUTED BICYCLIC AND TETRACYCLIC QUINONES AND RELATED METHODS OF USE | The Regents of the University of Michigan (US) | 2024-09-11 | — | — | EP | disclosed |
| EP-3439640-B1 | NANOPARTICLES FOR DRUG DELIVERY TO TREAT BONE DISEASE | CLEVELAND CLINIC FOUND (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-3471712-B1 | SMALL MOLECULE INHIBITORS OF ALDH AND USES THEREOF | UNIV MICHIGAN REGENTS (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-3233085-B1 | QUINAZOLINE COMPOUNDS AS INHIBITORS OF EGFR AND PI3K | UNIV MICHIGAN REGENTS (US) | 2022-09-07 | — | — | EP | disclosed |
| CN-114450287-A | SHP2 phosphatase inhibitors and methods of making and using the same | 传达治疗有限公司 | 2022-05-06 | — | — | CN | disclosed |
| EP-3285583-B1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | UNIV MICHIGAN REGENTS (US) | 2021-03-17 | — | — | EP | disclosed |
| EP-3131544-B1 | MDM2 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2018-12-12 | — | — | EP | disclosed |
| US-20110250243-A1 | NANOPARTICLE COMPOSITIONS | NOVARTIS AG (CH) | 2011-10-13 | — | — | US | disclosed |
| EP-2369014-A1 | Compositions and methods for characterizing, regulating, diagnosing and treating cancer | The Regents Of The University Of Michigan Office Of Technology Transfer (US) | 2011-09-28 | — | — | EP | disclosed |
| EP-2141173-A1 | Methods and compositions for the inhibition of gene expression | Pronai Therapeutics, Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| US-20060275308-A1 | Combination of gallium compounds with nonchemotherapeutic anticancer agents in the treatment of neoplasia | GENTA INCORPORATED | 2006-12-07 | — | — | US | disclosed |
| US-20060210639-A1 | Nanoparticulate bisphosphonate compositions | ELAN PHARMA INTERNATIONAL LIMITED | 2006-09-21 | — | — | US | disclosed |
| US-20050203612-A1 | Luminal prostheses which allow for programmed and controlled delivery of mycophenolic acid or derivatives with increased efficacy to selected locations within a patient's vasculature to inhibit restenosis and hyperplasia | AVANTEC VASCULAR CORPORATION (US) | 2005-09-15 | — | — | US | disclosed |
| EP-1539041-A1 | DEVICES DELIVERING THERAPEUTIC AGENTS AND METHODS REGARDING THE SAME | Avantec Vascular Corporation (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20050125054-A1 | Devices delivering therapeutic agents and methods regarding the same | AVANTEC VASCULAR CORPORATION (US) | 2005-06-09 | — | — | US | disclosed |
| US-20040191328-A1 | Combination of gallium compounds with nonchemotherapeutic anticancer agents in the treatment of neoplasia | SYNGENTA CROP PROTECTION AG (CH) | 2004-09-30 | — | — | US | disclosed |
| WO-2004010900-A1 | DEVICES DELIVERING THERAPEUTIC AGENTS AND METHODS REGARDING THE SAME | AVANTEC VASCULAR CORPORATION (US) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250295678-A1 | ULTRA LOW DOSAGE ZOLEDRONIC ACID FOR TREATMENT OF RETINAL DISEASE | FDPS, SMPD1, SMPD2 | FDPS 1/4885MMP8 2342/4885BTN3A1 1910/4885 |
| US-20110250243-A1 | NANOPARTICLE COMPOSITIONS | EDNRA, CD63, ECE1 | FDPS 2881/4885MMP8 661/4885BTN3A1 3254/4885 |
| US-20060210639-A1 | Nanoparticulate bisphosphonate compositions | ACP3, BPGM, SOST | FDPS 204/4885MMP8 2909/4885BTN3A1 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.